What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Law
David J. Nutt mainly focuses on Psychiatry, Neuroscience, Anxiety, Pharmacology and Clinical psychology.
His Psychiatry study frequently draws connections to other fields, such as Evidence-based practice.
As a part of the same scientific study, David J. Nutt usually deals with the Neuroscience, concentrating on Psychedelic experience and frequently concerns with Psychedelic therapy, Functional magnetic resonance imaging, Default mode network and Resting state fMRI.
His work in Pharmacology tackles topics such as Benzodiazepine which are related to areas like GABAA receptor and Antagonist.
His Panic disorder study also includes fields such as
- Panic which connect with Flumazenil,
- Serotonin, which have a strong connection to Neurotransmitter.
His studies deal with areas such as Cognition and MEDLINE as well as Depression.
His most cited work include:
- Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. (1044 citations)
- Drug harms in the UK: a multicriteria decision analysis. (907 citations)
- Development of a rational scale to assess the harm of drugs of potential misuse (821 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Psychiatry, Pharmacology, Internal medicine, Anxiety and Endocrinology.
Psychiatry is closely attributed to Clinical psychology in his study.
His Pharmacology research incorporates elements of Agonist, Receptor and Benzodiazepine.
He does research in Internal medicine, focusing on Serotonin specifically.
His study involves Anxiety disorder, Panic disorder and Generalized anxiety disorder, a branch of Anxiety.
David J. Nutt interconnects Antagonist and Idazoxan in the investigation of issues within Endocrinology.
He most often published in these fields:
- Psychiatry (29.99%)
- Pharmacology (17.15%)
- Internal medicine (16.90%)
What were the highlights of his more recent work (between 2013-2021)?
- Psychiatry (29.99%)
- Neuroscience (13.09%)
- Addiction (8.53%)
In recent papers he was focusing on the following fields of study:
David J. Nutt spends much of his time researching Psychiatry, Neuroscience, Addiction, Clinical psychology and Pharmacology.
Psychiatry is closely attributed to MEDLINE in his research.
Many of his studies involve connections with topics such as Receptor and Neuroscience.
His Addiction research incorporates themes from Alcohol dependence, Endocrinology, Psychotherapist, Internal medicine and Criminology.
His studies link Anxiety with Clinical psychology.
His research in Psilocybin is mostly concerned with Psychedelic therapy.
Between 2013 and 2021, his most popular works were:
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (402 citations)
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (356 citations)
- The dopamine theory of addiction: 40 years of highs and lows (335 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Psychiatry
- Law
David J. Nutt mainly investigates Psychiatry, Neuroscience, Clinical psychology, Addiction and Psilocybin.
His Psychiatry research includes themes of Alternative medicine and Internal medicine.
David J. Nutt focuses mostly in the field of Clinical psychology, narrowing it down to matters related to Anxiety and, in some cases, Biomarker and Neuroimaging.
His biological study spans a wide range of topics, including Alcohol, Alcohol dependence, Impulsivity, Dopamine and Opioid.
His Psilocybin research integrates issues from Psychotherapist, Treatment-resistant depression and Mood.
His Endogenous opioid research is multidisciplinary, relying on both Endocrinology and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
